What is Pharmasol?
Founded in 1973, Pharmasol operates as an integrated Contract Development and Manufacturing Organization (CDMO) with a specialized focus on topical and oral applications. The company distinguishes itself through deep technical expertise in both aerosol and non-aerosol product formats, including complex liquids, lotions, and gels. With a robust infrastructure comprising 142,000 square feet of cGMP-compliant facilities, Pharmasol provides a comprehensive suite of services that span the entire product lifecycle. Its strategic proximity to the Boston technology and academic corridor allows the firm to maintain a competitive edge in innovation and regulatory compliance, effectively addressing the technical hurdles inherent in modern pharmaceutical product development.
How much funding has Pharmasol raised?
Pharmasol has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in Pharmasol
PPP
Public-Private Partnership
What's next for Pharmasol?
With this major enterprise-level funding, Pharmasol is well-positioned to accelerate its operational capabilities and expand its service offerings. The capital injection will likely be directed toward enhancing its manufacturing throughput and upgrading its cGMP facilities to meet the evolving demands of the global pharmaceutical market. As the industry shifts toward more complex topical delivery systems, Pharmasol's focus on technical precision and regulatory excellence will be pivotal in maintaining its growth trajectory. Future strategic initiatives will likely prioritize the integration of advanced manufacturing technologies to further streamline production efficiency and support the scaling requirements of its diverse client base.
See full Pharmasol company page
